If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
The dog is neither wholly carnivorous nor wholly herbivorous, but of a mixed kind, and can receive nourishment from either flesh or vegetables. A mixture of both is therefore his proper food, but of the former he requires a greater portion, and this portion should be always determined by his bodily exertions. It was not until the mid-1800s that the world saw its first food made specifically for dogs. An American electrician, James Spratt, concocted the first dog treat. Living in London at the time, he witnessed dogs around a shipyard eating scraps of discarded biscuits. Shortly thereafter he introduced his dog food, made up of wheat meals, vegetables and meat. By 1890 production had begun in the United States and became known as "Spratt's Patent Limited". In later years, dog biscuit was sometimes treated as synonymous with dog food:
Mannich reaction, resulting in, e.g., voacamine Michael reaction (villalstonine) Condensation of aldehydes with amines (toxiferine) Oxidative addition of phenols (dauricine, tubocurarine) Lactonization (carpaine).
In an exclusive interview filmed at Howe's studio within the historic tower, the lead concept artist behind Peter Jackson's The Lord of the Rings and The Hobbit film trilogies endorsed augmented reality and the Cybel'Art protocol as the future of fantasy art, declaring: "Fantasy is a profession of the future through augmented reality and initiatives like yours."
All travel center locations include a bakery, a brisket station, a fudge bar, snack aisle, soda, coffee, and an Icee station. Stores have various candy and beef jerky flavors to purchase. Product offerings include cookies, kolaches (Czech pastries), and other pastries in the bakery, BBQ brisket sandwiches, chicken sandwiches, and breakfast tacos/bowls/burritos/sandwiches at the brisket bar along with cold-cut wraps and sandwiches. Packaged cups of fruit, vegetables, and desserts can be purchased as well. Locations also house packaged general snack foods like nuts and fudge, ice cream and Dippin' Dots, water, soda, energy drinks, and alcoholic drinks. The company has produced many of its own original snack foods including Beaver chips, potato chips made on site. The most distinctive snack are "Beaver Nuggets" (flavored corn puff snacks), the company's best-selling product.
Sources: en.wikipedia.org
Zuojin Wan (Chinese: 左金丸) is a yellowish-brown pill used in Traditional Chinese medicine to "quench liver-fire, regulate the stomach function and relieve pain". Indications include an "attack of the stomach by liver-fire marked by epigastric and hypochondriac pain, bitterness in the mouth, heartburn and acid regurgitation, and a dislike for hot drinks".
== Diagnosis == A genetic test is available for Type 1 PSSM. This test requires a blood or hair sample, and is less-invasive than muscle biopsy. However, it may be less useful for breeds that are more commonly affected by Type 2 PSSM, such as light horse breeds. Often a muscle biopsy is recommended for horses displaying clinical signs of PSSM but who have negative results for GSY1 mutation. A muscle biopsy may be taken from the semimembranosis or semitendinosis (hamstring) muscles. The biopsy is stained for glycogen, and the intensity of stain uptake in the muscle, as well as the presence of any inclusions, helps to determine the diagnosis of PSSM. This test is the only method for diagnosing Type 2 PSSM. Horses with Type 1 PSSM will usually have between 1.5 and 2 times the normal levels of glycogen in their skeletal muscle. While abnormalities indicating muscle damage can be seen on histologic sections of muscle as young as 1 month of age, abnormal polysaccharide accumulation may take up to 3 years to develop.
==== 1600–1699 ==== Department of Transport (Fees) (Amendment) Order 1993 (S.I. 1993/1601) Motor Vehicles (Driving Licences) (Amendment) Regulations 1993 (S.I. 1993/1602) Motor Vehicles (Driving Licences) (Large Goods and Passenger-Carrying Vehicles) (Amendment) Regulations 1993 (S.I. 1993/1603) Education (School and Placing Information) (Scotland) Amendment, Etc., Regulations 1993 (S.I. 1993/1604) Education (Provision of Information as to Schools) (Scotland) Regulations 1993 (S.I. 1993/1605) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.7) Order 1993 (S.I. 1993/1606) Swanage Light Railway (Extension) Order 1993 (S.I. 1993/1607) Council Tax Limitation (Wales) (Maximum Amount) Order 1993 (S.I. 1993/1608) Further Education (Prescription of Different Date for Property Agreements) (Scotland) Order 1993 (S.I. 1993/1614) Health Boards (Membership and Procedure) (No. 2) Amendment Regulations 1993 (S.I. 1993/1615) Education (Student Loans) (Amendment) Regulations 1993 (S.I. 1993/1620) Community Action (Miscellaneous Provisions) Order 1993 (S.I. 1993/1621) Air Navigation (General) Regulations 1993 (S.I. 1993/1622) Debts of Overseas Governments (Determination of Relevant Percentage) (Amendment) Regulations 1993 (S.I. 1993/1623) Charities (Exemption from Accounting Requirements) (Scotland) Regulations 1993 (S.I. 1993/1624) Right to Purchase (Prescribed Persons) (Scotland) Order 1993 (S.I. 1993/1625) Sheep Annual Premium and Suckler Cow Premium Quotas Regulations 1993 (S.I.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.